Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data

Who May Qualify: - Patients whose EUS results indicates pancreatic cystic or cystoid lesions; - Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN); - Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET). Who Should NOT Join This Trial: - Patients whose age is less than 18 years old; - Patients who have undergone pancreatic surgery before the EUS examination; - Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination; - Pathological results indicate that pancreatic lesions are metastatic lesions from other sites; - Patients whose EUS images or reports are missing; - EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image; - Patients whose final diagnosis is unclear. Always talk to your doctor about whether this trial is right for you.